RT Journal Article
SR Electronic
T1 The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.20.22280161
DO 10.1101/2022.09.20.22280161
A1 R.N. Thompson
A1 E. Southall
A1 Y. Daon
A1 F.A. Lovell-Read
A1 S. Iwami
A1 C.P. Thompson
A1 U. Obolski
YR 2022
UL http://medrxiv.org/content/early/2022/09/20/2022.09.20.22280161.abstract
AB A key feature of the COVID-19 pandemic has been the emergence of SARS-CoV-2 variants with different transmission characteristics. However, when a novel variant arrives in a host population, it will not necessarily lead to many cases. Instead, it may fade out, due to stochastic effects and the level of immunity in the population. Immunity against novel SARS-CoV-2 variants may be influenced by prior exposures to related viruses, such as other SARS-CoV-2 variants and seasonal coronaviruses, and the level of cross-reactive immunity conferred by those exposures. Here, we investigate the impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants in a simplified scenario in which a novel SARS-CoV-2 variant is introduced after an antigenically related virus has spread in the population. We use mathematical modelling to explore the risk that the novel variant invades the population and causes a large number of cases, as opposed to fading out. If cross- reactive immunity is complete (i.e. someone infected by the previously circulating virus is no longer susceptible to the novel variant), the novel variant must be more transmissible than the previous virus to invade the population. However, in a more realistic scenario in which cross-reactive immunity is partial, we show that it is possible for novel variants to invade, even if they are less transmissible than previously circulating viruses. This is because partial cross-reactive immunity effectively increases the pool of susceptible hosts that are available to the novel variant compared to complete cross-reactive immunity. Furthermore, if previous infection with the antigenically related virus assists the establishment of infection with the novel variant, as has been proposed following some experimental studies, then even variants with very limited transmissibility are able to invade the host population. Our results highlight that fast assessment of the level of cross-reactive immunity conferred by related viruses on novel SARS-CoV-2 variants is an essential component of novel variant risk assessments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementRNT was funded by the EPSRC through the Mathematics for Real-World Systems CDT (grant number EP/S022244/1). The collaboration between RNT and SI was supported by an International Exchange grant from the Royal Society (grant number IES\R3\193037) and a Computer Science Small Grant from the London Mathematical Society. YD and UO were supported by a grant from Tel Aviv University Center for AI and Data Science in collaboration with Google, as part of the initiative of AI and Data Science for social good. FALR was funded by the BBSRC through the Oxford Interdisciplinary Bioscience DTP (grant number BB/M011224/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/yairdaon/waning